Bi­cy­cle Ther­a­peu­tics banks a $52M B round for the next leg of the long R&D jour­ney ahead

A trans-At­lantic biotech with one foot in Cam­bridge, UK and an­oth­er plant­ed in Cam­bridge, MA has raised close to $52 mil­lion as it looks to beef up its staff and steer a range of its unique­ly de­signed drug con­ju­gates in­to the clin­ic.

Bi­cy­cle Ther­a­peu­tics won back­ing from a long list of mar­quee in­vestors: Ver­tex Ven­tures led the round with help from new in­vestors Cam­bridge In­no­va­tion Cap­i­tal and Christophe West­phal’s Long­wood Fund. Bi­cy­cle’s ex­ist­ing in­vestors – No­var­tis Ven­ture Fund, Glax­o­SmithK­line’s SROne, SVLS and At­las Ven­ture — all came back for the B round.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.